CTOs on the Move

Luca Technologies

www.lucatechnologies.com

 
Luca Technologies, Inc. engages in the development of long-term biotechnology-driven solutions to the natural gas market in the United States.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Applied Biosystems, part of Life Technologies

Applied Biosystems, part of Life Technologies is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Applied Biosystems, part of Life Technologies is based in San Mateo, CA. You can find more information on Applied Biosystems, part of Life Technologies at www.appliedbiosystems.com

Evanston Regional Hospital

Evanston Regional Hospital is your community healthcare provider; a 42-bed facility with complete inpatient and outpatient care. We believe in the power of people to create great care. We`re more than 50 healthcare professionals strong. We are a Joint Commission accredited facility. And we work hard every day to be a place of healing, caring and connection for patients and families in the community we call home.

The California Poison Control System (CPCS)

The California Poison Control System (CPCS) is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Biolab

From our humble beginnings in Decatur, GA, in 1955, BioLab today is a leader in providing solutions for recreational and industrial water treatment and home cleaning. Our sales are now in excess of 600 million dollars annually and the stock of our parent

Alector

Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel therapeutics for Alzheimer`s disease, other forms of dementia, and mechanistically related neurodegenerative disorders. Alector`s strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. This approach is enabled by a strategic alliance with Adimab, the industry leader in discovery and optimization of antibody therapeutics. Alector is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months. Alector has incorporated a highly integrated and lean biotechnology structure with extensive outsourcing that supports core scientific and management teams.